These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 8318064)

  • 21. Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia.
    Goldammer A; Wiltschnig S; Heinz G; Jansen M; Stulnig T; Hörl WH; Derfler K
    Metabolism; 2002 Aug; 51(8):976-80. PubMed ID: 12145769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
    Schettler VJJ; Ringel J; Jacob S; Julius U; Klingel R; Heigl F; Roeseler E; Grützmacher P;
    Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis.
    Kawashiri MA; Nohara A; Higashikata T; Tada H; Nakanishi C; Okada H; Konno T; Sakata K; Hayashi K; Inazu A; Mabuchi H; Yamagishi M
    Atherosclerosis; 2017 Oct; 265():225-230. PubMed ID: 28926730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Liposorber Study Group.
    Gordon BR; Kelsey SF; Dau PC; Gotto AM; Graham K; Illingworth DR; Isaacsohn J; Jones PH; Leitman SF; Saal SD; Stein EA; Stern TN; Troendle A; Zwiener RJ
    Am J Cardiol; 1998 Feb; 81(4):407-11. PubMed ID: 9485128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The potential of mipomersen, an ApoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease.
    Vogt A; Parhofer KG
    Expert Opin Pharmacother; 2013 Apr; 14(6):691-7. PubMed ID: 23477485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Biological efficacy of LDL apheresis in major hypercholesterolemia].
    Dairou F; Assogba U; Bruckert E; De Gennes JL; Turpin G
    Ann Med Interne (Paris); 1994; 145(5):328-32. PubMed ID: 7985942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [LDL apheresis in the treatment of hyperlipoproteinemia].
    Ishikawa K
    Nihon Rinsho; 1994 Dec; 52(12):3298-302. PubMed ID: 7853726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipoprotein apheresis efficacy, challenges and outcomes: A descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989-2017.
    Pottle A; Thompson G; Barbir M; Bayly G; Cegla J; Cramb R; Dawson T; Eatough R; Kale V; Neuwirth C; Nicholson K; Payne J; Scott J; Soran H; Walji S; Watkins S; Weedon H; Nath Datta DB
    Atherosclerosis; 2019 Nov; 290():44-51. PubMed ID: 31563836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study).
    Waldmann E; Vogt A; Crispin A; Altenhofer J; Riks I; Parhofer KG
    Atherosclerosis; 2017 Apr; 259():20-25. PubMed ID: 28279833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of a new LDL apheresis system using two dextran sulfate cellulose columns in combination with an automatic column-regenerating unit and a blood cell separator.
    Knisel W; Müller M; Besenthal I; di Nicuolo A; Rebstock M; Risler T; Eggstein M
    J Clin Apher; 1991; 6(1):11-5. PubMed ID: 2045376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective continuous removal of low density lipoproteins by dextran sulfate cellulose column adsorption apheresis in the therapy of familial hypercholesterolemia.
    Stefanutti C; Isacchi GC; Antonini R; Bucci A; Cardillo A; Di Nucci GD; Gozzer M; Malagnino F; Masci M; Mazzarella B
    Beitr Infusionsther; 1988; 23():172-82. PubMed ID: 2484773
    [No Abstract]   [Full Text] [Related]  

  • 32. Effectiveness of LDL-apheresis in preventing restenosis after percutaneous transluminal coronary angioplasty (PTCA): LDL-apheresis angioplasty restenosis trial (L-ART).
    Yamaguchi H; Lee YJ; Daida H; Yokoi H; Miyano H; Kanoh T; Ishiwata S; Kato K; Nishikawa H; Takatsu F
    Chem Phys Lipids; 1994 Jan; 67-68():399-403. PubMed ID: 8187240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels.
    Kroon AA; van't Hof MA; Demacker PN; Stalenhoef AF
    Atherosclerosis; 2000 Oct; 152(2):519-26. PubMed ID: 10998482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LDL-apheresis in treatment of two patients with heterozygous familial hypercholesterolemia and extremely elevated lipoprotein (a) levels.
    Bambauer R; Schiel R; Latzo R; Klinkmann J
    Transfus Sci; 1995 Dec; 16(4):375-81. PubMed ID: 10159508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of severe hyperlipidemia: six years' experience with low-density lipoprotein apheresis.
    Bambauer R; Schiel R; Latza R; Klinkmann J
    Artif Organs; 1996 Apr; 20(4):336-9. PubMed ID: 9139620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety measures for low density lipoprotein apheresis treatment using dextran sulfate cellulose columns.
    Koga N
    Ther Apher; 1999 May; 3(2):155-60. PubMed ID: 10341391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of circulating miRNAs in patients with familial hypercholesterolaemia treated by LDL/Lp(a) apheresis.
    Dlouha D; Blaha M; Blaha V; Fatorova I; Hubacek JA; Stavek P; Lanska V; Parikova A; Pitha J
    Atheroscler Suppl; 2017 Nov; 30():128-134. PubMed ID: 29096828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disease control via intensified lipoprotein apheresis in three siblings with familial hypercholesterolemia.
    Taylan C; Schlune A; Meissner T; Ažukaitis K; Udink Ten Cate FE; Weber LT
    J Clin Lipidol; 2016; 10(6):1303-1310. PubMed ID: 27919346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term experience with extracorporeal low-density lipoprotein cholesterol removal by dextran sulfate cellulose adsorption.
    Schulzeck P; Olbricht CJ; Koch KM
    Clin Investig; 1992 Feb; 70(2):99-104. PubMed ID: 1600346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol.
    Lappegård KT; Enebakk T; Thunhaug H; Hovland A
    Atherosclerosis; 2016 Aug; 251():119-123. PubMed ID: 27318831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.